1 見出し1，12ポ，日本語ゴシック，英語Arial，段落後は6ポの設定です
|
|
|
- あかり みやくぼ
- 5 years ago
- Views:
Transcription
1 8. Page1 8. B 1 5) 6) mg 19 (1) 1) (a) 78.9% 30/ % 5/ % 10/1485.7% 12/ % 5/
2 8. Page2 (b) % 1562/ % 1298/ % 472/ % 592/ % 6/7 85.3% 81/ % 411/459 2 a) b) 10/ % 472/ % 12/ % 592/ % 1/2 81/ % 5/6 83.3% 411/ % 2/3 6/7 85.7% 3/3 -/- 33/ % 1562/ % a) b) % 37/
3 8. Page3 2) (a) C. albicans MIC 90 =0.5 µg/ml C. parapsilosis MIC 90 =4 µg/mlc. tropicalis MIC 90 =1 µg/mlc. guillermondii MIC=2 µg/mlc. glabrata MIC 80 =8 µg/ml non-albicans Candida spp. Cryptococcus neoformans MIC 90 =16 µg/ml (1)2)(b) Candida spp. 75.0% 24/ (2) Cryptococcus spp. 66.7% 4/ No. UK-292,663-JP )(d) MIC C. albicans 0.51 µg/ml non-albicans Candida spp µg/ml Cryptococcus spp µg/ml 3 C. albicans non-albicans Candida spp. Cryptococcus neoformans 3 MIC MIC µg/ml MIC C. albicans >64 Non-albicans Candida spp C. glabrata C. guilliermondii C. lusitaniae C. parapsilosis C. tropicalis Cryptococcus neoformans % 27/ (1) 91.7% 33/ % 28/31100% 5/ (1) B
4 8. Page4 (b) 50.0% 6/1275.0% 6/8100% 7/7100% 8/857.1% 4/ (3)1) % 59 96% % 6/7 7, 8) Cryptococcus neoformans Cryptococcus neoformans AIDS 9) AIDS ) % % 5/5 3)
5 8. Page5 (2) 1) (a) mg mg mg mg mg 200 mg mg 400 mg 800 mg mg
6 8. Page mg mg mg mg 200 mg mg mg mg 400 mg 400 mg 800 mg 400 mg 400 mg 400 mg 800 mg (b) mg % % 81.0% 1700/ % 38/ mg 77.2% 865/ % 379/ a) mg mg mg 100 mg 170/ % 104/ % 5/6 (83.3%) 279/385 (72.5%) 23/ % 47/ % 70/81 (86.4%) 349/ % 865/1121 (77.2%) 379/424 (89.4%) 233/ % 351/ % 117/ % 168/ % 4/6 66.7% 8/ % 2/2 1/1 1/1 586/736 (79.6%) 35/ % 274/ % 309/343 (90.1%) 895/ % a) /353 (81.0%) 30/ % 115/ % 145/165 (87.9%) 431/ % 299/370 (80.8%) 157/184 (85.3%) 13/17 (76.5%) 4/9 44.4% 8/ % 12/19 (63.2%) 25/ % 524/ % 631/ % 9/ % 1164/1491 (78.1%) 92/ % 444/ % 536/608 (88.2%) 1700/ % 100 mg 17.0% 8/ mg 11.1% 64/ mg 10.9% 134/ mg 9.2% 48/519
7 8. Page7 6 % mg mg mg 100 mg 48/ / /578 8/47 9.2% 10.9% 11.1% 17.0% 254/ % 400 mg (c) B B 1 5) mg 77%, 367/476 B mg/kg 71%, 249/350 B B 45% 145/322 8% 15/ ) 10) 7 B B mg/kg/ mg 77% 367/476 71% 249/350 45% 145/322 8% 15/181 B mg 6) mg 2000 mg mg 11) 400 mg 2000 mg 800 mg 1600 mg 800 mg 2) (a)
8 8. Page (1) mg 793 mg 500 mg 397 mg µg/ml 59 96% 54.9% 8 14 µg/ml (2)(b)d) (2)(b)d) (2)3)(a) Candida spp. MIC C. albicans 0.83 µg/ml non-albicans Candida spp. 2.0 µg/ml (1)6)(e) MIC C. glabrata Crypcococcus neoformans MIC 80 8 µg/ml (1)2)b) PK 400/200 mg ) MIC )(3) PK MIC 1000 mg 2 C. albicans (b) mg mg 73.8% 31/ mg mg 800/400 mg 81.8% 9/11400/200 mg 76.2% 16/21200/100 mg 62.5% 5/8400/200 mg 78.1% 25/32 200/100 mg 62.5% 5/8 8800/400 mg 81.8% 9/11400/200 mg 64.3% 9/14 400/200 mg 100% 7/7200/100 mg 62.5% 5/8 800/400 mg 400/200 mg 400/200 mg ) mg 400 mg mg 200 mg
9 8. Page /400 mg 400/200 mg 200/100 mg 2/3 4/8 -/- 0/1 a) 6/ % 3/4 2/3 -/- 1/1 b) 6/8 75.0% 4/4 3/3 -/- -/- 7/7 100% 9/ % 9/ % -/- 1/2 19/ % -/- 4/4 4/4 -/- 8/8 100% -/- 3/3 1/4 -/- 4/7 57.1% -/- 7/7 5/8 12/15 -/- 100% 62.5% 80.0% 9/11 16/21 5/8 31/ % 76.2% 1/2 62.5% 73.8% 25/ % a) 800 mg 400 mg CLCr 200 mg b) 400 mg 200 mg 400 mg (c) mg/kg mg/kg/ (1) mg/kg 1 90 mg/kg 36 mg/kg/ (3) mg/kg 36 mg/kg (1) AUC1007 µg h/ml, 748 µg h/ml AUC 357 µg h/ml mg/kg 2000 mg/kg 2 1,000 mg 793 mg mg 397 mg
10 8. Page mg 1600 mg 1000 mg 800 mg (1) 23.2% 22/ % 5/ (2) 800/400 mg 27.8% 10/36 400/200 mg 23.5% 8/34 200/100 mg 6.7% 1/ (2)1)(b) 24.3%, 25/ /400 mg 18.5% 5/27 800/400 mg (2)2)(b) 3) 1/ mg 73.8% 31/ % 33/ % 24/33 800/400 mg 400/200 mg 72.0% 18/25 400/200 mg 100% 7/7 200 mg 77.2% 865/ % 379/424
11 8. Page11 800/400 mg 400/200 mg mg 11.1% 64/ mg 10.9% 134/ mg 9.2% 48/ mg 800 mg 800 mg mg mg mg 400/200 mg 800/400 mg 800/400 mg 100% 21/21 p mg mg mg mg mg mg 400 mg 2
12 8. Page mg mg mg mg mg mg mg mg mg 400 mg mg 800 mg Infectious Diseases Society of America, Alexandria, VA ) 6 mg/kg/ 70 kg 400 mg ) ) mg 1) Rex, JH, Bennett JE, Sugar AM, Pappas PG, van der Horst, CM, Edwards JE et al. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. New Eng J Med 1994; 331: ) Nguyen MH, Peacock Jr JE, Tanner DC, Morris AJ, Nguyen ML, Snydman DR et al. Therapeutic approaches in patients with candidemia. Evaluation in a multicenter, prospective, observational study. Arch Intern Med 1995; 155: ) Anaissie EJ, Vartivarian SE, Abi-Said D, Uzun O, Pinczowski H, Kontoyiannis DP et al. Fluconazole versus amphotericin B in the treatment of hematogenous candidiasis: A matched cohort study. Am J Med 1996; 101: ) Viscoli C, Castagnola E, Van Lint MT, Moroni C, Garaventa A, Rossi MR et al. Fluconazole versus amphotericin B as empirical antifungal therapy of unexplained fever in granulocytopenic cancer patients: a pragmatic, multicentre, prospective and randomised clinical trial. Eur J Cancer
13 8. Page ; 32A: ) Phillips P, Shafran S, Garber G, Rotstein C, Smaill F, Fong I et al. Multicenter randomized trial of fluconazole versus amphotericin B for treatment of candidemia in non-neutropenic patients. Eur J Clin Microbiol Infect Dis 1997; 16: ) Anaissie EJ, Kontoyiannis DP, Huls C, Vartivarian SE, Karl C, Prince RA et al. Safety, plasma concentrations, and efficacy of high-dose fluconazole in invasive mold infections. J Infect Dis 1995; 172: ) Saag MS, Graybill RJ, Larsen RA, Pappas PG, Perfect JR, Powderly WG et al. Practice guidelines for the management of cryptococcal disease. Clin Infect Dis 2000; 30: ). a). 1997; 33: ).. ;1999. P ) Kontoyiannis DP, Bodey GP, and Mantzoros CS. Fluconazole vs. amphotericin B for the management of candidaemia in adults: a meta-analysis. Mycoses 2001; 44: ). AIDS. ; 1993: ) Rex JH, Walsh TJ, Sobel JD, Filler SG, Pappas PG, Dismukes WE et al. Practice guidelines for the treatment of candidiasis. Clin Infect Dis 2000; 30: ). Empiric Therapy Jap J Antibio 1997; 50: ). Jap J Antibio 1998; 51:
14 8. Page14 (3) 100/200/ (1) (1) (2) (3) [ (1)] 6 (1) (2) [ ] (3) [] (1) (2) (3) (2)
15 8. Page15 (1)) (2)
16 8. Page16 (1) 1
17 8. Page17
18 8. Page18 (2) 肝臓 皮膚 消化器 精神 神経系 腎臓 代謝異常 血液 循環器 呼吸器筋 骨格系 その他 (1) (2)
19 8. Page19 (2) (1) mg/ 1600mg/ 2000mg/ 18) (2) 8200mg 48 (1) [ ] (2) 10mL/ ) 2)
1 見出し1，12ポ，日本語ゴシック，英語Arial，段落後は6ポの設定です
5. Page1 5. (1) 500 /mm 3 500 /mm 3 1,2,3) CDC Centers for Disease Control and Prevention, Atlanta ational osocomial Infections Surveillance Candida spp. 4 7.3 16.1% 4,5) 1980 1989 AIDS 1997 100,000 0.3
特殊病態下感染症における抗菌薬治験の手引き作成委員会報告書（案）
VOL.51 NO.6 JUNE 2003 JUNE 2003 9) Niederman MS et al: Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy and prevention.
THE JAPANESE JOURNAL OF ANTIBIOTICS 65 2 Apr NTT NTT
Apr. 2012 THE JAPANESE JOURNAL OF ANTIBIOTICS 65 2 121 23 7 7 IDSA 122 24 THE JAPANESE JOURNAL OF ANTIBIOTICS 65 2 Apr. 2012 7 2005 3 10 7 2011 6 2 NTT NTT 2011 6 Apr. 2012 THE JAPANESE JOURNAL OF ANTIBIOTICS
Candida albicans In Vitro Diagnostics (13)--D-Glucan Determination Reagents
D 012 Candida albicans In Vitro Diagnostics (13)--D-Glucan Determination Reagents DATA : 1 DATA : 2 3 DATA : UNGITEC 1 1 DATA : 20pg/mL 1020pg/mL 10pg/mL (cut off 20pg/mL) 90.2%(37/41) 100%(85/85) 96.8%(122/126)
THE JAPANESE JOURNAL OF ANTIBIOTICS 65 2 Apr non-albicans 4 non-albicans C. glabrata, C. parapsilosis, C. tropicalis, C. krusei 4 C. guil
Apr. 2012 THE JAPANESE JOURNAL OF ANTIBIOTICS 65 2 111 13 B ACTIONs Bundle ACTIONs Bundle 2009 7 ACTIONs Bundle ACTIONs project Appropriate Candidal Treatment, Implementation Of Nonneutropenic strategies
1.8.2 Page MIC () MIC 50 / MIC 90 µg/ml Candida albicans (54) / Candida glabrata (25) 0.25 / 0.5 Candida guilliermondii a) (2)
1.8.2 Page1 1.8.2 96% 2002 40 B 1 123 (1) in vitro 1) in vitro C. glabrata C. krusei 1 2 19951997 3 1999 2002 MIC MIC 2 1.8.2 Page2 1 19951997 MIC () MIC 50 / MIC 90 µg/ml Candida albicans (54) 0.016 /
Rinku General Medical Center
Rinku General Medical Center 4860 100 1620 Ann Intern Med. 1966; 64: 328 40 CHOP 63 1 83 J Clin Oncol. 1998; 16: 20065-69 Febrile Neutropenia IDSA(Infectious Diseases Society of America) 2002 Guidelines
A A
3 A B C A A 2 5 1 62 A 1 1 2 63 3 1 A proven invasive fungal diseases 1 2 3 BAL 24 : Fusarium spp. 4 2 : Candida Trichosporon B probable invasive fungal diseases Cpossible invasive fungal diseases 5 1
Key words: yeast, Etest(R), microdilution method, MIC Table 1 MICs of quality control strains The data shown are the range of MIC performed in triplicate Table 2 Renge of MICs, MIC50s and MIC90s for 81
37, 9-14, 2017 : cefcapene piperacillin 3 CT Clostridium difficile CD vancomycin CD 7 Clostridium difficile CD CD associate
37, 9-14, 2017 : 36 2015 8 6 cefcapene piperacillin 3 CT Clostridium difficile CD vancomycin 20 1983 2016 3 CD 7 Clostridium difficile CD CD associated diarrhea : CDAD CD 1,2 PPI 3 1 36 33 2015 8 6 5 5
SBP hospitalist network.key
1 Treatment and Prophylaxis of Spontaneous Bacterial Peritonitis (1); (2), (3). (1) (2) (3) :, :, 2 Clinical Question 1 72...,.,,.,... 3. CT..,. 4? SBP? SBP. 5 Clinical Question SBP? SBP,? 6 SBP (Spontaneous
要望番号 ;Ⅱ-183 未承認薬 適応外薬の要望 ( 別添様式 ) 1. 要望内容に関連する事項 要望者学会 ( 該当する ( 学会名 ; 日本感染症学会 ) ものにチェックする ) 患者団体 ( 患者団体名 ; ) 個人 ( 氏名 ; ) 優先順位 1 位 ( 全 8 要望中 ) 要望する医薬品
未承認薬 適応外薬の要望 ( 別添様式 ) 1. 要望内容に関連する事項 要望者学会 ( 該当する ( 学会名 ; 日本感染症学会 ) ものにチェックする ) 患者団体 ( 患者団体名 ; ) 個人 ( 氏名 ; ) 優先順位 1 位 ( 全 8 要望中 ) 要望する医薬品 要望内容 成分名 ( 一般名 ) 販売名 会社名 国内関連学会 未承認薬 適応 外薬の分類 ( 該当するものにチェックする )
C/NC : committed/noncommitted
C/NC : committed/noncommitted 110 time post-icd implant 1) The Cardiac Arrhythmia Suppression Trial (CAST) Investigators Preliminary report : Effect of encainaide and flecainide on mortality in a
! 1Munderl P et al. Survival and causes of death, 2 years after Introduction of antiretroviral therapy in Africa. XVI International AIDS Conference, 2006, Abstract THLB0208. 2Walensky RP et al. The
E Societe de Pathologie Infectieuse de Langue Francaise (, 1991) E Spanish Thoracic Society (1992) E American Thoracic Society (ATS : 1993. ü ù2001 ) E British Thoracic Society (1993, ü è2001 ) E Canadian
CHEMOTHERAPY FEB. 1994
CHEMOTHERAPY FEB. 1994 CHEMOTHERAPY FEB. 1994 Table 1. In vitro effect of flucytosine combined with fluconazole on Candida app. Fig. 1. Chemotherapeutic effect of combinations of flucytosine and uconazole
VOL.42 NO.3 R= H: Itraconazole R=OH: Hydroxy-itraconazole (R 63373) Fig. 1. Structures of itraconazole and hydroxyitraconazole. Candida albicans, Candida glabrata, Candida guilliermondii, Candida tropicalis,
) Meropenem Chemotherapy (Tokyo) ) panipenem/betamipron Chemotherapy (Tokyo) ) Meropenem Chemotherapy (Toky
2.7 2.7.5 1) 199846410-437 2) UTI ( )UTI ( 3 )Chemotherapy (Tokyo) 1986 34408-441 3) () 199745762-778 4) 1992 5) 199543 6) Chemotherapy (Tokyo) 199139687-689 7) Imipenem/Cilastatin sodium (MK-0787/MK-0791)
Key words: Candida, fungemia, antifungal activity, micafungin, fluconazole-resistant
Key words: Candida, fungemia, antifungal activity, micafungin, fluconazole-resistant Fig. 1 Annual changes in percentages of fungi isolated from blood and vascular catheters Fig. 2 Frequencies of fungi
400 46 THE JAPANESE JOURNAL OF ANTIBIOTICS 65 6 Dec. 2012 LVFX 100 mg 3 / 7 150 mg 2 / 7 2 2006 2008 9 LVFX PK PD 2009 7 100 mg 1 3 500 mg 1 1 AUC/MIC
Dec. 2012 THE JAPANESE JOURNAL OF ANTIBIOTICS 65 6 399 45 2012 11 5 LVFX 500 mg 1 1 20 Chlamydia trachomatis C. trachomatismycoplasma genitalium M. genitalium LVFX 1 500 mg 1 1 7 22 22 C. trachomatis 17
感染症学雑誌第80巻第6号
Candida Candida albicans Candida parapsilosis Candida glabrata Candida tropicalis C. albicans C. grabrata C. tropicalis µ Candida guilliermondii µc. parapsilosis µ Candida µcandida C. albicans µ µ µ µ
50mg 75mg (1) H 3 C O OH HO H O O H OH SO H 3 Na H H N H 2 N NH OH H N O O H H O OH H 3 C H O O N H H H HO H NH CH 3 HN HO H OH O H OH H NH
3240 14 8 8 50mg 75mg 13 6 25 1-(1) H 3 C O OH HO H O O H OH SO H 3 Na H H N H 2 N NH OH H N O O H H O OH H 3 C H O O N H H H HO H NH CH 3 HN HO H OH O H OH H NH O N O C 56 H 70 N 9 NaO 23 S 1292.26 5-[(1S,2S)-2-
Table 1 Eight clinical cases with candidemia gra.; granulocytopenia (<400/ml) before candidemia AMoL; acute monocytic leukemia VH; intravenous yperali
Key words: candidemia, HA-test, Cand-Tec, D-arabinitol, Ĉ-d-glucan Table 1 Eight clinical cases with candidemia gra.; granulocytopenia (
_02三浦.indd
36, 7-11, 2016 IPD PCV 5 3 80% 1 invasive pneumococcal disease ; IPD 2010 7 PCV7 2013 13 PCV13 IPD IPD 2,3 2015 1 2015 12 5 1 IPD 2015 1 12 IPD 5 IPD 1 4 2 5 http://pneumocatch.jp/ 5 Statens Serum Institut
2009年133巻3号3月号.indb
Folia Pharmacol. Jpn.133 1 2 Chiroscience UCB S RR-..% AA C IC C/A A/ A R- II/ III II/III Chiroscience UCB S 1 - E-mail: koji_taya@maruishi-pharm.co.jp Author: Koji Taya, Satoshi Shimizu Title: Levobupivacaine
Understanding Stem Cell Transplant 2007
Understanding Stem Cell Transplant IMF International Myeloma Foundation 12650 Riverside Drive, Suite 206 North Hollywood, CA 91607 USA Telephone: 800-452-CURE (2873) (USA & Canada) 818-487-7455 Fax: 818-487-7454
Synagis RS RSRespiratory Syncytial Virus RSBPD CHDRS RS RS BPD CHD 50mg100mg RS20138 RS Respiratory Syncytial Virus RS
RS Synagis RS RSRespiratory Syncytial Virus RSBPD CHDRS RS RS1998 7020021BPD 200510CHD 50mg100mg2012 812 RS20138 RS Respiratory Syncytial Virus RS 28 12 29 35 6 6BPD24 24CHD 24 24 28 2935 RS 12 6 RS BPD
がん患者の終末期ケアにおける通所リハビリテーションの役割 介護保険によるがん終末期ケアの可能性
2 3 3 6 7 49 53 13 61 22 27 65 68 34 47 71 73 4 5 7 6 8 9 10 11 12 13 14 15 44 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4
要望番号 ;Ⅱ-24 未承認薬 適応外薬の要望 ( 別添様式 ) 1. 要望内容に関連する事項 要望者 ( 該当するものにチェックする ) 学会 ( 学会名 ; 特定非営利活動法人日本臨床腫瘍学会 ) 患者団体 ( 患者団体名 ; ) 個人 ( 氏名 ; ) 優先順位 8 位 ( 全 33 要望中
未承認薬 適応外薬の要望 ( 別添様式 ) 1. 要望内容に関連する事項 要望者 ( 該当するものにチェックする ) 学会 ( 学会名 ; 特定非営利活動法人日本臨床腫瘍学会 ) 患者団体 ( 患者団体名 ; ) 個人 ( 氏名 ; ) 優先順位 8 位 ( 全 33 要望中 ) 要望する医薬品 成 分 名 ( 一般名 ) 販 売 名 会 社 名 国内関連学会 amoxicillin-clabulanate
名称未設定-1
Study on Clinical Factors Affecting the Fungal Culture Test - Relevance of Dry Mouth - Yoshiko YAMAMURA, Yukihiro MOMOTA, Hideyuki TAKANO, Koichi KANI, Katsumi MOTEGI, Fumihiro MATSUMOTO, Masayuki AZUMA
untitled
1) American College of Surgeons:Advanced Trauma Life Support Course Manual. American College of Surgeons 1997;103-112 24 2) American Society of Anesthesiologists Task Force:Practice guideline for blood
胆石症
,. vs 64 .. vs. -, Ransohoff DF, Gracie W. Treatment of gallstones. Ann Intern Med ; 119 : - Halldestam I, Enell EL, Kullman E, et al. Development of symptoms and complications in individuals with asymptomatic
untitled
19 CSPOR CRC/2009.8.8-9 2009 8 8 ( ) - CSPOR CRC SEMINAR- twatanab@oncoloplan.com http://www.oncoloplan.com - Toru Watanabe MD - 2 Phase I: Dose Finding trial Phase II : Efficacy and Safety trial Phase
ひとくちメモ/山口英世先生
Epidemiology of antifungal resistance : current status and future perspective Hideyo YAMAGUCHI 2 4 6 4 9 4 MCZ MCFG 7 4 MRSA Candida spp. MCZ a B b MCFG P45 4αCYP5 c DNA d CYP5 CYP5,3-D-,3-D-,3-D- a b
164 SDD & SOD SDD E100 mg 80 mg B500 mg 2 E 2 B 48 /59 81 SDD SOD 10 /63 16 RCT RCT 1992 Gastinne 15 ICU 445 SDD E100 mg 80 mg B 10
163 特 集 SDD & SOD SDD(Selective digestive decontamination),sod(selective oropharynx decontamination), 腸内細菌叢, 耐性菌 Ⅰ はじめに SDD Selective digestive decontamination SOD Selective oropharynx decontamination
200mg 2005 3 876179 2002 3 3 200mg VFEND for Intravenous Use (1) (2) [4.1 ] (3) [4.2 ] (1) [1] (2) (3) [1] 3
日本化学療法学会雑誌第56巻第3号
β Key words Candida albicans albicans Candida C. albicans Candida glabrata Candida krusei albicans Candida C. glabrata C. albicans albicans Candida β in vitro in vivo C. glabrata C. krusei I β γ µ Candida
fl:a-221 fr:(a_222 [-O-72 3 li-o)-80 u-o-40 u-o-74 [-O-16 III-O-i3 lr-{o-2e 1 tr-g2e.3 rrr-g3e fi-o-zs rrr{tsr8 [+1e ll1g41 )isatracurium besylate besylate li-gr2 -omitapide iegenon )harmaceuticals #it
2001 2003 2005 2006 2007 2008
2001 2003 2005 2006 2007 2008 60 etc. http://nosmoke.hp.infoseek.co.jp/yuugaibussitu.htm http://nosmoke.hp.infoseek.co.jp/yuugaibussitu.htm 23.5% 2.8% 2.8% 3.4% 30.3% 9.9% 11.5% 15.8% AAN 65
051
Aug. THE JAPANESE JOURNAL OF ANTIBIOTICS 58 4 389( 15 ) 1. MDS collagenase 2. 1 3. 4. / 390( 16 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 58 4 Aug. 4 4 2004 10 2 1 NTT Aug. THE JAPANESE JOURNAL OF ANTIBIOTICS
2 2 THE JAPANESE JOURNAL OF ANTIBIOTICS 67 1 Feb. 2014 4 5 CRBSI Catheter related bloodstream infection 1. n 167 I. 4 4, 6 5 71% 7 10 Candida albicans
Feb. 2014 THE JAPANESE JOURNAL OF ANTIBIOTICS 67 1 1 1 1, 3 2, 3 1 2 3 2013 11 13 CRBSI compromised host CRBSI 4 CVC CVC 1 3 - -D- / 1 ICU 2, 3 4 2 2 THE JAPANESE JOURNAL OF ANTIBIOTICS 67 1 Feb. 2014
13●53頁●６－７▲院内感染対策▲.ppt
No.610 1 No.121 2 No.128 Nosocomial infection, Hospital-acquired infection CDC nosocomial infection, hospital-acquired infection nosocomial nosokomeion hospital nosocomial infection nosocomial pneumonia
14UNAIDS HIV 39% i 9 ii9iii UNAIDS x.9x.9x1= ?? UNAIDS % 77%8% 44.7x.77x.8x1=
DeCEMBER, 17 No.34 HIV 169-73 1-1-1-13TEL 3-5937-4413:3 19:3 FAX 3-5937-443E-mail info@janpplus.jp http://janpplus.jp/!9-9-9!... 1-3 POSITIVE HIV/AIDS UNAIDS!... 4-5 JaNP+HIV Cafe Bar an opportunity...
慢性膵炎
- - 121 , g CCK g g - kgkcal kgkcal - g,,, - G.I.Res ; 10 : - ; 13 : - ; 22 : - Meier RF, Beglinger C. Nutrition in pancreatic diseases. Best Pract Res Clin Gastroenterol ; 20 : - Pfutzer RH, Schneider
JHN Journal Club 手稲渓仁会病院
JHOSPITALIST network GUIDE-IT trial; The Guiding Evidence Based Therapy Using Biomarker Intensified Treatment in Heart Failure multicentre randomised clinical trial 20171010 1 70 (EF 30%), (PCI), (HbA1c
23 3 11 14 46 9.0 7 10m 40.1m 15,883 2,681 25 4 10 39 40 800 180 24 2425 22 21 24 5 3 21 24 10,899 20,472 13,723 33,007 667 400 79,167 8,620 11,694 10,089 25,131 690 215 56,439 13,614 20,897 15,200 32,213
1 2 D- D- 1206 D- D- -2003 120 /2004 D-FDA GRAS D D- 3 5 5 D- 75 10g/kg 14 40 20 D-101520 90 1520 20%101520 1520 D- 5(D- 2300-6700mg//) () 2024 615 D- 41220g/kg/ 1220g/kg/ 20g/kg/ 1220g/kg/ () 50 D- 10%
untitled
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 1 24 25 26 27 1 28 1 1 2 2 3 3 k k 1 2 3 k 29 30 31 32 33 () 34 35 36 () 37 () () () 38 39 40 41 42 43 2 2 44 45 46 47 48 49 50 51 52 53 54 55
原 著 日集中医誌.2010;17:33 ~38. 深在性真菌症の診断 治療における β-d- グルカン値の評価 *1 *1, 2, 5 *3 藤木早紀子志馬伸朗廣瀬有里 *4 *3, 5 小阪直史藤田直久 要約 : 目的 深在性真菌症の診断における β-d- グルカン (BDG) の測定意義と適正
原 著 日集中医誌.2010;17:33 ~38. 深在性真菌症の診断 治療における β-d- グルカン値の評価 *1 *1, 2, 5 *3 藤木早紀子志馬伸朗廣瀬有里 *4 *3, 5 小阪直史藤田直久 要約 : 目的 深在性真菌症の診断における β-d- グルカン (BDG) の測定意義と適正な適用 評価法を考察した 方法 単一大学病院の感染症検査室および薬剤部データベース解析により, 1998
20mg #tr#5*xlj lffin&+'.':, t) r+'z)vt '+D#J Centers for Medicare & Medicaid Sewices Garden AS et al. Preliminary results ofradiation Therapy Oncology Group 97-03: a randomized phase II trial of
untitled
2303 16 2 9 1 14 5 31 (423) 1 (4), (6) C55H84ClN17O21S3 HCl (BLM-A2) 1487.47 11 2 1 4 104 2 14 5 31 [ ] ( ) ( ) 1. 15mg 30mg( ) 5 20mL 1 5mg( ) 2. 3 15mg 30mg( ) 5mL 1mg( ) 1mL 3. 5mg 15mg( ) 4. 1 2 1
胆石症
ESWL ESWL LC QALE LC RCT cm 76 ESWL ESWL - - mm US X CT HU ESWL - ESWL ESWL UDCA, ESWL, UDCA, ESWL 77 Mirizzi - ; 90 : - Nicholl JP, Brazier JE, Milner PC, et al. Randomised controlled trial of cost-effectiveness
VOL.42 S-1
CHEMOTHERAPY APR. 1994 VOL.42 S-1 CHEMOTHERAPY APR. 1994 Table 1. Criteria for evaluation of clinical efficacy by the Japanese Society of Oral and Maxillo-Facial Surgeons Grades of symptoms and numerical
食道がん化学放射線療法後のsalvage手術
2006 2 17 52 Daly JM, et al. J Am Coll Surg 2000;190:562-573 Esophageal Cancer: Results of an American College of Surgeons Patient Care Evaluation Study Daly JM, et al. J Am Coll Surg 2000;190:562-573
32 1 BRONJ BRONJ II BRONJ BRONJ 4 BP BRONJ 6 1 III BP BRONJ
29 1 31 40 2014 31 Bisphosphonate related osteonecrosis of jaw; BRONJ 2008 4 2012 3 36 98 8 11 19 BRONJ 0 13 2 5 3 1 1 0 BP 4 15 10 5 α-streptococcus 0 BRONJ BRONJ BP I Paget 1 409-3898 1110 2014 1 27
青森県2012-初校.indd
http://www.kairyudo.co.jp/ 2012 AOMORI 2 3 9 16 1 2 3 2010 6 128.9 128.2 128.7 8 9 31.7 30.0 31.7 30.0 22.5 21.4 21.9 21.0 117.2 116.7 116.3 115.8 65.1 64.9 64.7 64.5 7 25.3 24.0 24.9 23.5 123.1 122.5
6 12 10661 93100 227213202 222208197 85kg cm 20 64.521 106856142 2 1 4 3 9767 100 35 cm 7747 208198 90kg 23 5828 10661 93100 cm 227213202 10639 61 64.521 85kg 78kg 70kg 61 100 197204.5 cm 15 61
<82D282A982C1746F95F18D908F57967B95B E696E6464>
1 2 (90cm 70cm 2015) 3 (68cm 28cm 30cm 12kg 2015) (77.5 109.5cm 2015) 4 (22cm 50cm 50cm 4.6kg 2015) (45cm 62.5cm 2015) (47.4cm 62.5cm 2014) 5 (28.5cm 23.5cm) (45cm 62cm 2015) (97cm 107cm 2015) 6 7 8 9
180 140 22
21 180 140 22 23 25 50 1 3 350 140 500cm 600 140 24 25 26 27 28 29 30 31 1/12 8.3 1/15 6.7 10 1/8 12.5 1/20 140 90 75 150 60 150 10 30 15 35 2,000 30 32 1 1 1 2 1 3 1 4 1 5 1 6 1 7 1 8 1 9 % 100 50 33.3
38 38 THE JAPANESE JOURNAL OF ANTIBIOTICS 66 1 Feb CT A B A CT B 20xx 2 8 LAM 20xx 1 12 CT S6, S10 Aspergillus spp. Micafungin MCFG 150 mg/ I
Feb. 2013 THE JAPANESE JOURNAL OF ANTIBIOTICS 66 1 37 37 Liposomal amphotericin B 1 2 2 2 1 1 1 2 1 1 2 2012 12 25 33 Lymphangioleiomyomatosis: LAM 2 20xx 1 CT Aspergillus spp. Micafungin MCFG Itraconazole
*Criteria 1) B-marker positive 2) Variability in nuclear size and shape 3) Giant cells and multinucleated cells
*Criteria 1) B-marker positive 2) Variability in nuclear size and shape 3) Giant cells and multinucleated cells Abbreviation: LC=large cleaved nuclei, LNC=large non-cleaved nuclei, IMBL=immunoblastic nuclei,
橡
TP T-13i AST ALT ALP Y CTP LOH CHE CRP 8.7 id 0.4 mg/d 21 AWL 131U/L 257 LU/L 12 111/L 234 11J/L 344 IU/L 0.30 mid No K a BUN ORE UA 142 meq/1 4.3 meqa 108 meqa 15.8 met! 0.71 mg/di 5.0 mg/d CEA 5_5 n8/m1
24 RS 24 RSRespiratory Syncytial Virus RS BPD24 24CHD RS RS BPD CHD
Immunocompromised Children 24 RS24 24 RS 24 RSRespiratory Syncytial Virus RS 28 12 29 35 6 6BPD24 24CHD 24 24 1 RS 28 2935 12 6 RS BPD 246 1 1 CHD 24 24 24 2 RS [1] [1.1] RS 24 RS T DiGeorge Wiskott- Aldrich
本文.indd
CQ ACC/AHA PECO PatientExposure Comparison OutcomePECO low-density lipoprotein cholesterol LDL C cholesterol cholesterol intensive OR agressive CQ target LDL C PubMed Systematic Reviews Clinical Study
untitled
( ) - 1 - - 2 - 38% 26% A) Response to ifosfamide and mesna: 124 previously treated patients with metastatic or unresectable sarcoma 124 (J Clin Oncol 7: 126-131, 1989) 124 95 29 II 1 2,000mg/m 2 x 4 8g/m
5.3mg () 1 2SD 2 1.5SD 17 15 2 4 4 3 ( ) 瘙 3 嘔 気 嘔 吐 腹 痛 消 化 不 良 便 秘 4 24 p * p ** IGF-I (ng/ml) 77.12±60.19 238.97±143.60 161.85±113.30 [124.08, 199.63] (p
CTD 2 2.6 5.3mg 0.4mg 0.6mg 0.8mg 1.0mg 1.2mg 1.4mg 1.6mg 1.8mg 2.0mg 12mg 2.6 Page 3 2.6.6...5 2.6.6.1...6 2.6.6.2...9 2.6.6.3...9 2.6.6.4... 11 2.6.6.5... 11 2.6.6.6... 11 2.6.6.7... 11 2.6.6.8... 11
untitled
19 11 13 300 18 3 31 1300mg 4 6 C 15 H 22 FN 3 O 6 359.35 + -1-5--β-D--5--1,2--2- -4- 19 11 13 300 18 3 31 A B B A 30 1 2 21 7 1 1 1.31m 2 900mg 1.31m 2 1.64m 2 1,200mg 1.64m 2 1,500mg B 30 1 2 14 7 1
VENTANA ALK D5F3 Rabbit Monoclonal Antibody OptiView ALK D5F3
VENTANA ALK D5F3 Rabbit Monoclonal Antibody OptiView ALK D5F3 2 OptiView ALK D5F3 11 10 79.3%31% 18% 80 85NSCLC 40% 1,2 1 1018 ALK ALK 2 ALK 3 5% ALK EML4 EML4-ALK Coild-Coil ALK ALK 3,4,5 2 6 EGFR 50%
Key words : candidemia, endotoxin, D-arabinitol, Candida antigen, serological examination
Key words : candidemia, endotoxin, D-arabinitol, Candida antigen, serological examination Fig. 1 The value of fungal index and D- arabinitol/creatinine. Fungal index was mesured by Endotoxin D and Endospecy
20mg CTD 2.4 2.4 2.4... 5 2.4.1... 5 2.4.2... 7 2.4.3... 10 2.4.4... 13 2.4.5... 18 2.4.6... 20 3 2.4 2.4 2.4.1 JNS002 ( HSPC) N-(Carbonyl-methoxypolyethylene glycol 2000)-1,2- distearoyl-sn-glycero-3-phosphoethanolamine
<30332D D8CB492982D FC95E490E690B62D8FAC8FBC96BE90E690B62E706466>
A questionnaire survey on the use of placebo in clinical practice by nurses in Japan 1 1 2 2 1 4 1964 5, 6 1998 GCP 1 School of Nursing, Faculty of Medicine, Toho University 2Faculty of Medical Technology,
DIC vegetation 1 nonbacterial thrombogenic e
2001 2002 Guidelines for the Prevention and Treatment of Infective Endocarditis (JCS 2003) h 1 1 2 3 4 5 6 7 8 9 2 1 2 3 1 2 3 4 1 2 5 1 2 1 G Streptococcus viridans Streptococcus bovis 2 G Streptococcus
日本化学療法学会雑誌第54巻第S-1号
β β Key words β Candida krusei Candida glabrata β I β Drugadministration Baselinecharacteristics Clinicalsymptom Mycologicaltests Plasmadrugconcn Adverseevents Laboratorytests ) -leadecg Clinicalphotograph
秋田県2012-初校.indd
http://www.kairyudo.co.jp/ 2012 AKITA 2 3 4 10 15 1 2 3 2 cm 110.7 111.6 109.8 110.6 5 kg 19.0 19.5 18.6 19.1 cm 61.9 62.2 61.5 61.6 cm 116.7 117.8 115.8 116.8 6 kg 21.4 22.5 21.0 21.9 cm 64.9 65.4 64.5
THE JAPANESE JOURNAL OF ANTIBIOTICS 68 3 June 2015 Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis % 2 S. pneumon
June 2015 THE JAPANESE JOURNAL OF ANTIBIOTICS 68 3 189 49 1 : 14 1 2 2 3 1 2 3 2015 4 3 1 : 14 CVA/AMPC 1 : 14 27 CVA/AMPC 1 : 14 88.5% Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis
化学療法剤の適切な使い方について
1 2 3 4 5 6 7 Che E, in Cancer: Principles & Practice of Oncology (7th ed) in Devita, 2005 Marangolo M, Oncol Rep, 2006 hryniuk WM, Important Adv Oncol, 1988 8 Cancer: Principles & Practice of Oncology
Atlas_j060419
Hill s Atlas of Veterinary Clinical Anatomy 1 29 30 2 3 4 5 31 32 33 34 35 36 37 6 7 8 9 10 11 12 13 38 39 40 41 14 15 16 17 18 19 20 21 22 23 24 25 26 27 42 43 44 45 46 47 48 49 50 51 52 53 54 55 28 81
山口英世先生
Laboratory diagnosis of imported mycoses : how to safely execute laboratory examinations Hideyo YAMAGUCHI 5 1 6 1 1976 7 019-0395 359 Teikyo University Institute of Medical Mycology (TIMM) (359 Otsuka,
Key words: bacterial meningitis, Haemophilus influenzae type b, Streptococcus pneumoniae, rapid diagnosis, childhood
Key words: bacterial meningitis, Haemophilus influenzae type b, Streptococcus pneumoniae, rapid diagnosis, childhood Fig.1 Distribution of the cases with bacterial meningitis by age and pathogens Chiba
エクラー軟膏0.3%、エクラークリーム0.3%、エクラーローション0.3%_IF
2005 1 872646 IF 1998 9 1g 3mg(0.3%) Deprodone Propionate 2003227 200374 1997415( ) 1998316( ) F A X 2003 7 1992 3 17 1997 10 9 1992 5 22 1997 12 19 IF 2005 4 IF 1. MR 63 2 IF 10 3 IF 2. IF IF IF 3. IF
岩手県2012-初校.indd
http://www.kairyudo.co.jp/ 2012 IWATE 2 3 4 16 1 2 3 2 14 165.6 165.2 55.2 54.3 88.6 88.1 cm kg cm 13 160.1 159.7 50.1 49.1 85.1 84.9 12 153.5 152.5 46.3 44.2 81.9 81.3 13 155.4 154.9 48.9 47.3 84.2 83.7
資料 3 1 医療上の必要性に係る基準 への該当性に関する専門作業班 (WG) の評価 < 代謝 その他 WG> 目次 <その他分野 ( 消化器官用薬 解毒剤 その他 )> 小児分野 医療上の必要性の基準に該当すると考えられた品目 との関係本邦における適応外薬ミコフェノール酸モフェチル ( 要望番号
資料 3 1 医療上の必要性に係る基準 への該当性に関する専門作業班 (WG) の評価 < 代謝 その他 WG> 目次 小児分野 医療上の必要性の基準に該当すると考えられた品目 との関係本邦における適応外薬ミコフェノール酸モフェチル ( 要望番号 ;II-231) 1 医療上の必要性の基準に該当しないと考えられた品目 本邦における適応外薬ミコフェノール酸モフェチル
日本化学療法学会雑誌第58巻第2号
Key words β Candida Table1. MCFGCPAstudygroup Investigator (representative) YoshitsuguMiyazaki NaoyukiMiyashita RyoichiAmitani KenjiOgawa AtsuyukiKurashima ToshiroKiguchi MichiakiMishima YuichiInoue HiroshiSaito
(1) (2) (3) (1) (2) (3) (1) (2) (3) (4) (1) (2)
(1) (2) (3) (1) (2) (3) (1) (2) (3) (4) (1) (2) (1) (2) (3) (1) (2) (3) (1) (2) (3) vs. (2) (1) 16 22 143,977 24,030 55,769 600 (2) (3) (4) (1) (2) (1) (2) 2 (3) (abuse) (1) (2) (3) (1) (2) (3)
d-00
283-0105 298 TEL. 0475-76-0839 FAX. 0475-76-0838 400g 300 4950399167708 14 220g 300 4950399066780 Page 1 300g 200 4950399066766 100 400g 300 4950399167722 350g 160 4950399066735 100 600g 350 4950399167685
「長寿のためのコレステロール ガイドライン2010 年版」に対する声明
長寿のためのコレステロールガイドライン 2010 年版 に対する声明 平成 22 年 9 月 1 日に 脂質栄養学会 コレステロールガイドライン策定委員会 という組織から 標記 ガイドライン 1) が発表された この内容をめぐる一部のメディアの報道により 一般の方々のみならず 患者やその家族の方々の間にも コレステロールに関する認識に 混乱を招いている 日本動脈硬化学会は 動脈硬化性疾患予防ガイドライン
CHEMOTHERAPY AUG. 1982 VOL. 30 NO. 8 CHEMOTHERAPY Fig.1 Relation between various-closis of cefazolin and detection rate of organisms in heart blood of dying mice with E. coli and P. aeruginosa infection
Fig. 1 Clinical findings and extent of inflammation area in female urethrocystitis Fig. 2 Classification and distribution of female patients with blad
Key words: Female with bladder irritability, Subjective symptoms, Pyuria, Bacteriuria Fig. 1 Clinical findings and extent of inflammation area in female urethrocystitis Fig. 2 Classification and distribution
et al No To Shinkei Clin Neurol Neurology et al J Neurosurg et al Arch Neurol et al Angiology
37 Recommendations for the Management of Moyamoya Disease A Statement from Research Committee on Spontaneous Occlusion of the Circle of Willis (Moyamoya Disease) Research on intractable diseases of the
Ⅱ Ⅲ Ⅳ Assertive community treatment - Issues from scientific and clinical literature with implications for practice The Impact of Supported Employment and Working on Clinical and
indd
Molecular Targeted Therapy for Lung Cancer from a Pharmaceutical Point of Viewe Naho SASAKI epidermal growth factor receptor tyrosine kinase inhibitor :EGFR-TKI vascular endothelial growth factor:vegf
報告書 H22-2A-09
061-0293 1757 TEL 0133-23-1211 2.0% 0.5% in vitro QOL Quality of Life 1 MCE-400 400 mpa s Duck Algin 350M M/G 0.8 70 80 C 20% 50 C 1.0% 5 C SV-10 5 C 10 ml E TV 20H model E 1 34 R24 1 ml 5 C 30 6 12 30
日本化学療法学会雑誌第61巻第4号
μ μ μ μ μ μ Key words I β μ Sex Age (years) Height (cm) Evaluation items Table1.Characteristics of patients 1. mg/kg/day (n14) 2.5 mg/kg/day (n9) 5. mg/kg/day (n9) Total (n32) male 12 8 7 27 female 2 1
臨床神経 indd
164 41 3 CTS CTS Key Words : carpal tunnel syndrome, nerve conduction study, sensory nerve action potential CTS CTS 10 1 2 CTS 1 3 4 CTS 1 Tinel Phalen Tinel CTS 1 Phalen Phalen Phalen Phalen 2 1/3 : 1
/ US Difficult Airway Management US Difficult Airway Management DAM DAM / AW AW / FS FS LMA LMA LMA LMA LMA LMA / AW AW AW AW SLM SLM SLM SLM T MT2 MT2 QT QT ILMA ILMA LMA LMA LMA LMA A B C D ILMA ILMA